Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Change in Receivables (2022 - 2025)

Historic Change in Receivables for TriSalus Life Sciences (TLSI) over the last 4 years, with Q3 2025 value amounting to -$497000.0.

  • TriSalus Life Sciences' Change in Receivables fell 34126.21% to -$497000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $404000.0, marking a year-over-year decrease of 7827.96%. This contributed to the annual value of $1.7 million for FY2024, which is 1313.79% down from last year.
  • TriSalus Life Sciences' Change in Receivables amounted to -$497000.0 in Q3 2025, which was down 34126.21% from $174000.0 recorded in Q2 2025.
  • In the past 5 years, TriSalus Life Sciences' Change in Receivables ranged from a high of $940000.0 in Q3 2023 and a low of -$736000.0 during Q4 2022
  • Moreover, its 4-year median value for Change in Receivables was $363500.0 (2024), whereas its average is $250416.7.
  • Per our database at Business Quant, TriSalus Life Sciences' Change in Receivables soared by 196571.43% in 2024 and then tumbled by 34126.21% in 2025.
  • Quarter analysis of 4 years shows TriSalus Life Sciences' Change in Receivables stood at -$736000.0 in 2022, then surged by 168.21% to $502000.0 in 2023, then dropped by 28.09% to $361000.0 in 2024, then tumbled by 237.67% to -$497000.0 in 2025.
  • Its last three reported values are -$497000.0 in Q3 2025, $174000.0 for Q2 2025, and $366000.0 during Q1 2025.